Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques. by Broedl, Uli C. et al.
Low Adiponectin Levels Are an Independent Predictor of
Mixed and Non-Calcified Coronary Atherosclerotic
Plaques
Uli C. Broedl1.*, Corinna Lebherz2., Michael Lehrke1, Renee Stark3, Martin Greif2, Alexander Becker2,
Franz von Ziegler2, Janine Tittus2, Maximilian Reiser4, Christoph Becker4, Burkhard Go¨ke1, Klaus G.
Parhofer1, Alexander W. Leber2
1Department of Internal Medicine II, University of Munich, Munich, Germany, 2Department of Internal Medicine I, University of Munich, Munich, Germany, 3Helmholtz-
Zentrum, Munich, Germany, 4Department of Radiology, University of Munich, Munich, Germany
Abstract
Background: Atherosclerosis is the primary cause of coronary artery disease (CAD). There is increasing recognition that
lesion composition rather than size determines the acute complications of atherosclerotic disease. Low serum adiponectin
levels were reported to be associated with coronary artery disease and future incidence of acute coronary syndrome (ACS).
The impact of adiponectin on lesion composition still remains to be determined.
Methodology/Principal Findings: We measured serum adiponectin levels in 303 patients with stable typical or atypical
chest pain, who underwent dual-source multi-slice CT-angiography to exclude coronary artery stenosis. Atherosclerotic
plaques were classified as calcified, mixed or non-calcified. In bivariate analysis adiponectin levels were inversely correlated
with total coronary plaque burden (r =20.21, p = 0.0004), mixed (r =20.20, p = 0.0007) and non-calcified plaques (r =20.18,
p = 0.003). No correlation was seen with calcified plaques (r =20.05, p = 0.39). In a fully adjusted multivariate model
adiponectin levels remained predictive of total plaque burden (estimate: 20.036, 95%CI: 20.052 to 20.020, p,0.0001),
mixed (estimate: 20.087, 95%CI: 20.132 to 20.042, p = 0.0001) and non-calcified plaques (estimate: 20.076, 95%CI: 20.115
to 20.038, p = 0.0001). Adiponectin levels were not associated with calcified plaques (estimate: 20.021, 95% CI: 20.043 to
20.001, p = 0.06). Since the majority of coronary plaques was calcified, adiponectin levels account for only 3% of the
variability in total plaque number. In contrast, adiponectin accounts for approximately 20% of the variability in mixed and
non-calcified plaque burden.
Conclusions/Significance: Adiponectin levels predict mixed and non-calcified coronary atherosclerotic plaque burden. Low
adiponectin levels may contribute to coronary plaque vulnerability and may thus play a role in the pathophysiology of ACS.
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Introduction
Atherosclerosis is the primary cause of coronary artery disease
(CAD), one of the most common causes of illness and death
worldwide. There is increasing recognition that lesion composition
rather than size determines the acute complications of atheroscle-
rotic disease in humans. Several studies suggested that thin-cap
fibroatheroma (non-obstructive plaques) are prone to rupture and
result in acute coronary artery occlusions [1–3], whereas obstruc-
tive, calcified plaques result in clinically stable angina pectoris.
Initiation and progression of the atherosclerotic lesion are highly
complex processes, and many aspects of atherogenesis remain
incompletely understood. Ectopic visceral adipose tissue was linked
to the pathogenesis of atherosclerosis due to secretion of a multitude
of pro- and anti-atherogenic cytokines and adipokines [4]. More
recently, pericardial adipose tissue (PAT) was also reported to play
an important role in coronary atherosclerosis [5], presumably
through paracrine and vasocrine signaling of adipokines [6].
Adiponectin is the most abundant adipokine produced by
adipose tissue. Serum levels of adiponectin are markedly decreased
in patients with visceral obesity and states of insulin resistance such
as non-alcoholic fatty liver disease and type 2 diabetes [7,8]. There
is an ongoing debate regarding adiponectin’s significance for
CAD. Although experimental data do suggest an atheroprotective
effect [9], existing epidemiological data connecting adiponectin
and cardiovascular disease are controversial. Low adiponectin
levels have been linked to the presence of CAD [10] and were
shown to be a risk factor for CAD [11] and cardiovascular events
[12]. Low adiponectin levels were reported to be associated with a
higher risk of acute coronary syndrome, independent of other
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traditional metabolic and cardiovascular risk factors [13]. Low
adiponectin levels were also reported to be associated with the
progression of coronary artery calcification as determined by
electron-beam CT [14]. Furthermore, low serum adiponectin
levels were shown to be an independent predictor of the extent of
CAD and coronary lesion complexity as determined by coronary
angiography [15–17]. In contrast, other studies including a recent
meta-analysis of 7 prospective reports on adiponectin and
coronary heart disease in Western populations failed to show an
association between adiponectin and incident coronary heart
disease as well as secondary cardiovascular events in patients with
known CAD [18,19].
The angiographic assessment of coronary luminal stenosis has
been considered a surrogate marker of the severity of atheroscle-
rosis. However, coronary angiography has low predictive value to
assess atherosclerotic plaque burden or to predict acute coronary
syndrome events [20–22]. It does not allow to identify non-
obstructive coronary plaques or to determine the composition of
atherosclerotic plaques. Therefore, in the present study, we used
dual-source multi-slice CT (DSCT)-angiography to quantitatively
and qualitatively assess coronary artery plaques to test whether 1)
adiponectin serum levels are associated with coronary atheroscle-
rotic plaque burden and 2) adiponectin levels are associated with
coronary atherosclerotic plaque morphology.
Results
Baseline characteristics of the study population are shown in
Table 1. 303 consecutive patients with stable typical or atypical
chest pain underwent DSCT-coronary angiography to exclude
coronary artery stenosis.
In 60 patients no coronary plaques could be detected. The
median number of coronary plaques was 3 (IQR: 1–6; range: 0–
26). The median numbers of calcified, mixed and non-calcified
plaques were 1 (IQR: 0–3; range: 0–22, number of patients with
calcified plaques: 154), 0 (IQR: 0–1; range: 0–10, number of
Table 1. Baseline characteristics and CT-angiographic findings of the study population.
Characteristics n =303
Age (yrs) 63 (55–70)
Sex male 202
female 101
Body mass index (kg/m2) 26.2 (24.1–29.0)
Hypertension* yes 147
no 126
Diabetes mellitus* yes 20
no 253
Smoker{ yes 42
no 230
Family history of CAD{ yes 77
no 195
Laboratory profile LDL-cholesterol (mg/dl) 122 (95–149)
HDL-cholesterol (mg/dl) 52 (44–59)
Triglycerides (mg/dl) 143 (106–207)
hsCRP (mg/dl) 0.23 (0.05–0.54)
Adiponectin (mg/ml) 5.1 (3.3–7.8) (range 0.2–23.4)
Medical treatment{ Statin 120
Asa, Plavix or Marcumar 170
Betablocker 173
ACE-I or ARB 138
Diuretics 87
Insulin or OAD 16
Pericardial adipose tissue volume (ml)1 190 (132–259)
Number of coronary artery plaques (total)I 3 (1–6) (range 0–26)
Number of calcified plaques 1 (0–3) (range 0–22)
Number of mixed plaques 0 (0–1) (range 0–10)
Number of non-calcified plaques 0 (0–2) (range 0–9)
Values are presented as n or median (interquartile range).
*History of diabetes and hypertension is known in 273 patients.
{History of smoking and family history of CAD is known in 272 patients.
{Medication is known in 258 patients.
1Adequate image quality for evaluation of PAT volume was obtained in 287 patients.
IAdequate image quality for evaluation of coronary plaques was obtained in 281 patients.
doi:10.1371/journal.pone.0004733.t001
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patients with mixed plaques: 102) and 0 (IQR: 0–2; range: 0–9,
number of patients with non-calcified plaques: 126), respectively.
Correlations and associations between adiponectin and
cardiovascular risk factors
Serum adiponectin levels were positively correlated with HDL-
cholesterol (HDL-C) (r = 0.32, p,0.0001) and age (r = 0.16,
p = 0.005), yet negatively correlated with body mass index (BMI)
(r =20.26, p,0.0001) and triglycerides (r =20.32, p,0.0001)
(Table 2). Interestingly, adiponectin was negatively correlated with
PAT volume (r =20.24, p,0.0001). No correlation was seen with
LDL-cholesterol (LDL-C) (r = 0.09, p = 0.11) and high sensitivity
C-reactive protein (hsCRP) levels (r =20.04, p = 0.49).
Among demographic characteristics, smoking (p= 0.02) was
associated with lower adiponectin levels. No or borderline
association was seen with diabetes mellitus (p = 0.37), hypertension
(p = 0.13), and family history of CAD (p= 0.05).
Adiponectin is an independent negative predictor of
coronary atherosclerotic burden
In bivariate analysis, adiponectin levels were negatively
correlated with total number of coronary artery plaques
(r =20.21, p= 0.0004) (Table 2). In a fully adjusted multivariate
model containing age, sex, BMI, hypertension, diabetes mellitus,
smoking, family history of CAD, LDL-C, HDL-C, triglycerides,
hsCRP, medication and PAT volume, adiponectin levels were
predictive of coronary atherosclerotic plaque burden, i.e. an
increase in adiponectin levels by 27.8 mg/ml is associated with the
reduction of one atherosclerotic plaque (estimate:20.036, 95%CI:
20.052 to20.020, p,0.0001) (Table 3). Thus, based on the range
of adiponectin and the range of total plaque number, adiponectin
levels account for approximately 3% of the variability in total
plaque burden in our study population.
Adiponectin is inversely associated with mixed and non-
calcified coronary artery plaques
Adiponectin was negatively correlated with mixed (r =20.20,
p = 0.0007) and non-calcified plaques (r =20.18, p = 0.003)
(Table 2). No correlation was seen with calcified plaques
(r =20.05, p= 0.39). In fully adjusted multivariate models,
adiponectin levels remained a negative predictor of mixed and
non-calcified plaque burden. Thus, the number of mixed plaques
decrease by 1 for an 11.5 mg/ml increase in serum adiponectin
levels (estimate: 20.087, 95%CI: 20.132 to 20.042, p = 0.0001)
(Table 4). Furthermore, an increase in adiponectin levels by
13.2 mg/ml is associated with the reduction of one non-calcified
plaque (estimate: 20.076, 95%CI: 20.115 to 20.038, p = 0.0001)
(Table 5). Based on the range of adiponectin and the range of
mixed and non-calcified plaque numbers, adiponectin levels
account for approximately 20% of the variability in mixed and
non-calcified plaque burden.
After adjusting for traditional cardiovascular risk factors
adiponectin turned out to be significantly associated with calcified
plaques (Table 6). In a fully adjusted model, however, this
association was lost again (estimate: 20.021, 95%CI: 20.043 to
0.001, p = 0.06).
Discussion
Our study was designed to examine the relationship of
adiponectin with total coronary atherosclerotic plaque burden
and atherosclerotic plaque morphology in humans. We demon-
strate that 1) adiponectin levels are predictive of total coronary
plaque burden, and 2) adiponectin levels are inversely correlated
with the number of mixed and non-calcified plaques. No
Table 2. Correlations and associations between adiponectin
and cardiovascular risk factors.
Characteristics p
Age 0.16 0.005
Sex Male 4.7 (2.9–6.6) ,0.0001
Female 6.9 (4.1–10.1)
Body mass index (kg/m2) 20.26 ,0.0001
Actual hypertension Yes 5.0 (2.9–7.5) 0.13
No 5.1 (3.4–8.1)
History of diabetes mellitus Yes 4.2 (2.2–8.3) 0.37
No 5.0 (3.1–7.7)
Actual smoker Yes 3.9 (2.4–5.7) 0.02
No 5.3 (3.2–7.9)
Family history of CAD Yes 4.3 (2.5–7.5) 0.05
No 5.3 (3.4–7.9)
LDL-cholesterol (mg/dl) 0.09 0.11
HDL-cholesterol (mg/dl) 0.32 ,0.0001
Triglycerides (mg/dl) 20.32 ,0.0001
High-sensitivity CRP (mg/dl) 20.04 0.49
Pericardial adipose tissue (ml) 20.24 ,0.0001
Total number of coronary artery plaques 20.21 0.0004
Number of calcified plaques 20.05 0.39
Number of mixed plaques 20.20 0.0007
Number of non-calcified plaques 20.18 0.003
Values are presented as correlation coefficient or median (interquartile range).
Age (r = 0.38, p,0.0001) and HDL-cholesterol (r =20.21, p = 0.0003) as internal
controls of our data were significantly correlated with total plaque burden in
bivariate analysis.
doi:10.1371/journal.pone.0004733.t002
Table 3. Multivariate association of adiponectin levels with
coronary atherosclerotic plaque burden.
Coronary atherosclerotic plaque burden
estimate 95% CI p
Model 1* 20.057 20.072 to 20.043 ,0.0001
Model 2{ 20.048 20.063 to 20.033 ,0.0001
Model 3{ 20.041 20.056 to 20.025 ,0.0001
Model 41 20.037 20.053 to 20.021 ,0.0001
Model 5I 20.036 20.052 to 20.020 ,0.0001
Estimate and 95% CI for decrease in the number of total coronary
atherosclerotic plaques for an 1 mg/ml increase in serum adiponectin levels. Full
model 5 (including all parameters) is shown in Table S1 of the supplement.
*adjusted for age, sex and BMI.
{adjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking and family
history of CAD.
{adjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking, family
history of CAD, LDL-C, HDL-C, triglycerides and hsCRP levels.
1adjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking, family
history of CAD, LDL-C, HDL-C, triglycerides, hsCRP levels and medication.
Iadjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking, family
history of CAD, LDL-C, HDL-C, triglycerides, hsCRP levels, medication and PAT
volume.
doi:10.1371/journal.pone.0004733.t003
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significant correlation was seen with calcified plaques. Our data
suggest that the number of mixed and non-calcified plaques
decrease by 1 for each 11.5 mg/ml and 13.2 mg/ml increase in
serum adiponectin levels, respectively.
Pundziute et al. [23] reported that the number of coronary
segments with mixed plaques as determined by MSCT was an
independent predictor of acute cardiac events including cardiac
death, nonfatal myocardial infarction and unstable angina
requiring hospitalization. Hoffmann et al. [24] demonstrated that
in contrast to calcified plaques, non-calcified plaques as deter-
mined by MSCT were consistently present in culprit lesions of
patients with acute coronary syndrome. We have recently shown
that rapid progression of angiographic stenosis severity occurred
most frequently in coronary segments with non-calcified or
predominantly non-calcified plaques as determined by MSCT
[25]. Wolk et al. [13] reported that higher plasma adiponectin
levels were associated with a lower risk of acute coronary
syndrome, suggesting that the pathophysiological role of adipo-
nectin may be related to the stability of atherosclerotic plaque
rather than atherosclerotic burden. Our data indicate that
adiponectin may reduce the number of non-calcified and mixed
plaques without affecting stable calcified plaques. Consistent with
these observations, Marso et al. [26] showed in a very recent study
that low adiponectin levels were associated with lipid-rich yet not
calcified coronary plaques in non-diabetic patients in bivariate
analysis as determined by IVUS. Furthermore, Otake et al. [27]
demonstrated that the necrotic core component ratio of culprit
lesions as determined by IVUS in patients with acute coronary
syndrome was negatively correlated with adiponectin levels in
bivariate analysis. Therefore, the finding of an independent
association between adiponectin and non-calcified and mixed
coronary plaques may have important therapeutic and preventive
implications for decreasing the risk of acute coronary events.
Although the exact mechanisms of the negative association
between adiponectin and mixed and non-calcified plaques remain
to be determined, several possible explanations should be
considered. In addition to its beneficial effects on insulin sensitivity
and lipid metabolism [28], adiponectin exerts its vasculoprotective
effects through its direct actions on endothelial cells, monocytes,
macrophages and other inflammatory cells, platelets and smooth
muscle cells, thus modulating initiation and progression of
atherosclerosis. Adiponectin augments endothelial NO production
[29,30], inhibits ox-LDL–induced endothelial ROS generation
[31], suppresses the expression of endothelial adhesion molecules
[32–34], attenuates leucocyte-endothelium interactions [35] and
protects endothelial cells from apoptosis [36]. Furthermore,
adiponectin inhibits macrophage activation [37,38] and foam cell
formation [39], promotes the clearance of early apoptotic cells by
macrophages [40], inhibits smooth muscle cell proliferation
Table 4. Multivariate association of adiponectin levels with
mixed plaques.
Mixed plaques
estimate 95% CI p
Model 1* 20.090 20.127 to 20.053 ,0.0001
Model 2{ 20.078 20.115 to 20.040 ,0.0001
Model 3{ 20.080 20.120 to 20.041 ,0.0001
Model 41 20.083 20.126 to 20.039 0.0002
Model 5I 20.087 20.132 to 20.042 0.0001
Estimate and 95% CI for decrease in the number of mixed plaques for an 1 mg/
ml increase in serum adiponectin levels. Full model 5 (including all parameters)
is shown in Table S2 of the supplement.
*adjusted for age, sex and BMI.
{adjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking and family
history of CAD.
{adjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking, family
history of CAD, LDL-C, HDL-C, triglycerides and hsCRP levels.
1adjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking, family
history of CAD, LDL-C, HDL-C, triglycerides, hsCRP levels and medication.
Iadjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking, family
history of CAD, LDL-C, HDL-C, triglycerides, hsCRP levels, medication and PAT
volume.
doi:10.1371/journal.pone.0004733.t004
Table 5. Multivariate association of adiponectin levels with
non-calcified plaques.
Non-calcified plaques
estimate 95% CI p
Model 1* 20.091 20.126 to 20.057 ,0.0001
Model 2{ 20.082 20.117 to 20.048 ,0.0001
Model 3{ 20.082 20.120 to 20.044 ,0.0001
Model 41 20.074 20.112 to 20.036 0.0001
Model 5I 20.076 20.115 to 20.038 0.0001
Estimate and 95% CI for decrease in the number of non-calcified plaques for an
1 mg/ml increase in serum adiponectin levels. Full model 5 (including all
parameters) is shown in Table S3 of the supplement.
*adjusted for age, sex and BMI.
{adjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking and family
history of CAD.
{adjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking, family
history of CAD, LDL-C, HDL-C, triglycerides and hsCRP levels.
1adjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking, family
history of CAD, LDL-C, HDL-C, triglycerides, hsCRP levels and medication.
Iadjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking, family
history of CAD, LDL-C, HDL-C, triglycerides, hsCRP levels, medication and PAT
volume.
doi:10.1371/journal.pone.0004733.t005
Table 6. Multivariate association of adiponectin levels with
calcified plaques.
Calcified plaques
estimate 95% CI p
Model 1* 20.044 20.064 to 20.024 ,0.0001
Model 2{ 20.039 20.060 to 20.019 0.0001
Model 3{ 20.026 20.047 to 20.005 0.01
Model 41 20.022 20.044 to 20.000 0.05
Model 5I 20.021 20.043 to 0.001 0.06
Estimate and 95% CI for decrease in the number of calcified plaques for an
1 mg/ml increase in serum adiponectin levels. Full model 5 (including all
parameters) is shown in Table S4 of the supplement.
*adjusted for age, sex and BMI.
{adjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking and family
history of CAD.
{adjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking, family
history of CAD, LDL-C, HDL-C, triglycerides and hsCRP levels.
1adjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking, family
history of CAD, LDL-C, HDL-C, triglycerides, hsCRP levels and medication.
Iadjusted for age, sex, BMI, hypertension, diabetes mellitus, smoking, family
history of CAD, LDL-C, HDL-C, triglycerides, hsCRP levels, medication and PAT
volume.
doi:10.1371/journal.pone.0004733.t006
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[32,41] and antagonizes the stimulatory effect of TNF-a on
vascular smooth muscle cell calcification [42].
The present study has several strengths and limitations. Our
data support the concept that adiponectin is an important marker
in the pathogenesis of atherosclerosis since adiponectin remains
significantly associated with plaque morphology in a fully adjusted
multivariate model containing age, sex, BMI, hypertension,
diabetes mellitus, smoking, family history of CAD, LDL-C,
HDL-C, triglycerides, hsCRP, medication and PAT volume.
However, since this was an association study, our study does not
establish a causal relationship between adiponectin and coronary
plaque morphology. Furthermore, the clinical implications of our
results still need to be determined.
There are conflicting epidemiological data regarding the role of
adiponectin in atherosclerosis with some studies showing strong
inverse associations between adiponectin levels and CAD [10–17]
and others failing to detect any association [18,19]. Differences in
study design, population characteristics and statistical adjustments
may in part explain the apparent discrepancies. In addition,
different methods of CAD assessment (CT-angiography or IVUS
versus conventional angiography or CT-based assessment of
coronary artery calcification) may yield distinct results. Adiponec-
tin may modulate early stages of atherogenesis thus mainly
affecting the development of non-calcified or mixed plaques.
In the present study adiponectin is not correlated with calcified
plaques, the majority of coronary plaques in our study cohort.
Therefore, although statistically highly significant, adiponectin
levels are associated with a very modest decrease in total coronary
plaque burden accounting for only 3% of the variability in total
number of coronary plaques. In contrast, adiponectin accounts for
approximately 20% of the variability in mixed and non-calcified
plaque burden. Determination of the bioactive high molecular
weight form of adiponectin may have possibly resulted in an even
stronger association of adiponectin with plaque burden and
morphology. Overall, our data emphasize the importance of
additional risk factors in the pathogenesis of atherosclerosis.
Storage conditions of blood samples (e.g. storage time and
temperature) were suggested to alter adiponectin levels [43,44].
However, comparing adiponectin concentrations in serum aliquots
stored for 21 and 33 months at270uC, adiponectin levels were not
significantly different (p= 0.45) suggesting that storage conditions
did not impact on our results due to adequate specimen stability.
Finally, our study results may only be applicable to non-diabetic
patients. Diabetics were clearly underrepresented in the present
study (7% of patients). The small number of diabetic patients may
also explain the lack of association between adiponectin levels and
diabetes.
In summary, we demonstrate that adiponectin is inversely
associated with coronary plaque burden and mixed and non-
calcified plaques, suggesting an important role of adiponectin in
the pathogenesis of atherosclerosis and possibly in the pathophys-
iology of acute coronary syndrome.
Methods
Ascertainment of Subjects
303 consecutive patients who underwent DSCT-coronary
angiography for exclusion of coronary artery stenosis due to
stable typical or atypical chest pain, were recruited during 20
consecutive months from March 2006 to October 2007. After
providing informed written consent, study subjects were asked to
complete a brief questionnaire and have blood drawn. The study
protocol was approved by the Ethics Committee of the Ludwig-
Maximilians-University Munich, Germany.
Dual-source multi-slice CT-coronary angiography
CT-coronary angiography was performed using a Siemens
Definition scanner (Siemens Medical Solutions, Forchheim,
Germany) that uses two X-ray sources for image generation.
Tube voltage for CT-angiography was 120 kV for both tubes in
patients with a body weight .80 kg and 100 kV for those with a
weight ,80 kg. Current was 560 mA with modulation, and full
current between 30–50% to 80% of the cardiac cycle. Gantry
rotation time was 0.33 s, and pitch 0.2–0.44 adapted to the HR.
Per rotation 64 slices were generated with a collimation of
0.6 mm, leading to an isotropic voxel resolution of approximately
0.6 mm edge length and 0.2 mm3 volume. Before the scan,
nitroglycerine was administered sublingually. A bodyweight-
adapted volume of contrast agent (1.25 cm3/kg bodyweight,
Ultravist 370, Schering, Berlin, Germany) was injected continu-
ously at a calculated rate to achieve constant injection during 20 s.
The scan was started with a delay of 5 s after the density in the
aortic root exceeded a density value of 100 HU (bolus tracking). A
saline flush (100 cm3 at 5 cm3/s) was applied to maintain a
compact bolus. Axial images were reconstructed with 0.75 mm
slice thickness and 0.5 mm increment using a medium sharp
convolution kernel (B26f) and retrospective ECG gating. The
reconstructions were performed in 10% steps over the entire R-R
cycle using a single-segment algorithm that utilizes a quarter
segment of projection data from both detectors. In atrial
fibrillation, data were reconstructed in 50 ms steps.
Dual-source CT image analysis
Coronary analysis. In the first step, all reconstructed data
sets were evaluated at different ECG-phases for diagnostic image
quality and the optimal data set was then chosen for analysis. The
DSCT datasets were evaluated by two independent investigators
blinded to serum adiponectin levels using a dedicated cardiac
workstation (Siemens, Leonardo Circulation).
Atherosclerotic plaques were classified as calcified, mixed or non-
calcified as described previously [45]. Calcified plaques were
defined as lesions with a HU value above 130. Non-calcified
plaques were defined as structures clearly assignable to the vessel
wall (in at least two views) with densities less than the lumen
contrast. Plaques with,50% calcified plaque area were classified as
mixed. The coronary tree was segmented according to the
suggestions of the AHA into a 15 segment model. Each segment
was further divided into a proximal and a distal segment. Each
segment was then classified as containing either calcified, non-
calcified, mixed or no plaque. Based on the number of diseased
segments a plaque score was calculated. Adequate image quality for
evaluation of coronary plaques was obtained in 281 of 303 patients.
The interobserver agreement of the 2 investigators was 95% for
calcified plaques, 94% for mixed plaques, and 93% for non-
calcified plaques.
Pericardial fat assessment. The same images as for the
analysis of atherosclerotic plaques were used to determine PAT
volume. PAT volume was measured in ml using the volume analysis
software tool of the Siemens Leonardo Circulation workstation.
PAT volume was determined similar to the method described by
Gorter et al. [46]. We defined PAT as the adipose tissue
surrounding the myocardium. The upper cut off point in the axial
slices was the bifurcation of the pulmonary artery. Adequate image
quality for evaluation of PAT volume was obtained in 287 of 303
patients. The interobserver agreement for PAT volume was 95%.
Laboratory procedures
Blood samples were stored in aliquots at 270uC until analysis
(i.e. up to 21 months). Serum levels of adiponectin (mg/ml) were
Adiponectin and Plaque Imaging
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determined with a commercial enzyme-linked immunosorbent
assay (R&D, Wiesbaden, Germany). To determine whether
storage conditions may have affected adiponectin levels, adipo-
nectin concentrations in aliquots stored for 21 and 33 months at
270uC from 20 patients were measured. Adiponectin levels did
not differ significantly between the two timepoints (21 months:
5.661.2 (mean6standard deviation) mg/ml versus 33 months:
5.361.1 mg/ml; p = 0.45) indicating adequate specimen stability
under our storage conditions.
Plasma LDL-C, HDL-C and triglycerides were measured by
routine enzymatic methods. Determination of hsCRP levels was
performed at the Department of Clinical Chemistry (Campus
Grosshadern, University of Munich, Germany).
Statistical Analysis
Statistical analyses were performed using SAS 9.1 (Cary, NC)
software. Data are reported as n or median (interquartile range).
Spearman correlation and Wilcoxon two-sample test were used in
the bivariate analysis of adiponectin with other variables. A
generalized linear regression model was used to assess the
association of adiponectin serum levels with atherosclerotic plaque
burden, number of calcified plaques, mixed plaques or non-
calcified plaques adjusted for age, sex, BMI, diabetes, hyperten-
sion, family history of CAD, smoking, LDL-C, HDL-C,
triglycerides, hsCRP levels, medical treatment (statin, asa, plavix,
marcumar, betablockers, ACE inhibitors, angiotensin-receptor
blockers, diuretics, oral anti-diabetic drugs, insulin) and PAT
volume - possible confounders of adiponectin levels. All tests were
two-tailed with a 0.05 type I error rate.
Supporting Information
Table S1–S4 Full adjusted model (model 5) for total number of
coronary plaques, mixed, non-calcified and calcified plaques
Found at: doi:10.1371/journal.pone.0004733.s001 (0.05 MB
DOC)
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